JP2023541141A5 - - Google Patents

Info

Publication number
JP2023541141A5
JP2023541141A5 JP2023515306A JP2023515306A JP2023541141A5 JP 2023541141 A5 JP2023541141 A5 JP 2023541141A5 JP 2023515306 A JP2023515306 A JP 2023515306A JP 2023515306 A JP2023515306 A JP 2023515306A JP 2023541141 A5 JP2023541141 A5 JP 2023541141A5
Authority
JP
Japan
Prior art keywords
composition according
anticancer
pharmaceutical composition
cancer
elv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049297 external-priority patent/WO2022051721A1/en
Publication of JP2023541141A publication Critical patent/JP2023541141A/ja
Publication of JP2023541141A5 publication Critical patent/JP2023541141A5/ja
Pending legal-status Critical Current

Links

JP2023515306A 2020-09-04 2021-09-07 がんを治療するための組み合わせ組成物及び方法 Pending JP2023541141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074968P 2020-09-04 2020-09-04
US63/074,968 2020-09-04
PCT/US2021/049297 WO2022051721A1 (en) 2020-09-04 2021-09-07 Combination compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2023541141A JP2023541141A (ja) 2023-09-28
JP2023541141A5 true JP2023541141A5 (https=) 2024-09-17

Family

ID=80491570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515306A Pending JP2023541141A (ja) 2020-09-04 2021-09-07 がんを治療するための組み合わせ組成物及び方法

Country Status (4)

Country Link
US (1) US20230330094A1 (https=)
EP (1) EP4208167A4 (https=)
JP (1) JP2023541141A (https=)
WO (1) WO2022051721A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566359B1 (en) * 2002-05-20 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College 2,4,6-trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid esters as neuroprotective drugs
CL2007002404A1 (es) * 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
AU2016219517B2 (en) * 2015-02-09 2020-02-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
US20180104251A1 (en) * 2015-03-09 2018-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of glioblastoma
US11684599B2 (en) * 2017-03-20 2023-06-27 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Similar Documents

Publication Publication Date Title
JP2022537551A5 (https=)
JP2023130496A (ja) 癌治療のための併用療法
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
Kang et al. In vivo evaluation of oral anti-tumoral effect of 3, 4-dihydroquinazoline derivative on solid tumor
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2022508513A5 (https=)
CN118401259A (zh) 抗trop-2抗体偶联药物和其他治疗剂的组合用途
CN1511036A (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
US7879868B2 (en) Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
RU2004135307A (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
JP2023541141A5 (https=)
WO2025196671A1 (en) Imidazolinone derivative combined with pd-1 or pd-l1 inhibitor for use in the treatment of tumors
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2023531090A5 (https=)
WO2023281097A1 (en) Methods for treating cancer
US20250387405A1 (en) Pharmaceutical composition containing platinum drugs or platinum drug cocrystals, and use thereof
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
WO2009104152A1 (en) Combination treatment for ovarian cancer
WO2025241959A1 (zh) 抗体药物偶联物在预防或治疗疾病中的应用
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
RU2024119934A (ru) Фармацевтическая композиция, содержащая производное фталазинона, для совместного введения с противораковым лекарственным средством